February 15, 2019
Marker Therapeutics has formally relocated their corporate headquarters from Jacksonville, Florida to Houston, Texas. In addition, the Company has announced that it is now a resident company at Johnson & Johnson Innovation – JLABS (JLABS at TMC).
February 7, 2019
Marker Therapeutics appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development. In this role, she will be responsible for clinical development strategy, clinical study design, and medical oversight of the Company’s therapeutic product candidates. Dr. Koneru joins Marker Therapeutics from Eli Lilly and Company, where she served most recently as Associate Vice President of Immuno-Oncology.
February 6, 2019
Chief Financial Officer, Anthony H. Kim, to present a corporate overview at the upcoming BIO CEO & Investor Conference on Monday, February 11, 2019.
January 17, 2019
Peter L. Hoang to present a corporate overview at the upcoming Phacilitate Leaders World & World Stem Cell Summit 2019 on January 23, 2019.
January 15, 2019
Data from four abstracts—including three oral presentations—were accepted for presentation at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research 2019.
January 4, 2019
The Houston, Texas-based immuno-oncology group gave an update on five clinical trials.
January 3, 2019
The Company has announced a year-end update in five clinical trials using the Company’s therapeutic products, LAPP and MAPP multi-antigen targeted T cell (MultiTAA) therapies and TPIV200, its Folate Receptor Alpha (FRα) peptide cancer vaccine product candidate.
December 12, 2018
Marker Therapeutics has emerged out of a merger with Tapimmune to push forward new cell-based cancer vaccines.
December 6, 2018
President and CEO, Peter L. Hoang, will be participating at the Tumor Targeted Lymphocyte Summit.
November 27, 2018
Data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018).